Heart, kidney, diabetes โ and liver: what MASLD puts at risk
Fatty liver disease rarely causes symptoms, so it is easy to dismiss. But MASLD is a multisystem disease. It travels with โ and worsens โ heart disease, kidney disease and type 2 diabetes, and those conditions in turn push the liver toward fibrosis. For most patients, the heart is at greater risk than the liver.
Key takeaways
- MASLD is usually silent until fibrosis is advanced โ risk has to be looked for, not waited for.
- Cardiovascular disease is the leading cause of death in people with MASLD. Risk of heart attack and stroke is about 45% higher with MASLD and about 2.5-fold higher with more severe disease.
- MASLD raises the risk of chronic kidney disease by roughly 40% and type 2 diabetes by about 2-fold โ and diabetes in turn accelerates liver scarring.
- From F2 fibrosis onward, the risk of cirrhosis, liver cancer and liver-related death climbs steeply.
What this means for you
If you have MASLD, you need two kinds of protection at once: your liver needs to be staged and treated if scarring is present, and your heart and kidneys need the same attention we would give anyone with diabetes. The good news is that many of the same treatments do both.
A silent disease
Most people with MASLD โ even MASH with significant fibrosis โ feel well. Fatigue or a vague ache under the right ribs is sometimes reported but is nonspecific. By the time symptoms clearly point to the liver (jaundice, abdominal swelling, easy bruising, confusion, vomiting blood), cirrhosis is usually present. That is why guidelines recommend screening people at risk rather than waiting for symptoms (see Who should be checked).
Routine liver enzymes are an unreliable warning system. In a US diabetes-clinic study, most patients with liver fibrosis had ALT and AST under 40 U/L. Fatty liver is also often mentioned on imaging reports and never followed up.
Heart disease and cardiovascular death
A meta-analysis of 36 long-term studies including about 5.8 million people found that MASLD (then NAFLD) was associated with a ~45% higher risk of fatal or non-fatal cardiovascular events โ heart attack, stroke, heart failure, arrhythmia โ independent of age, sex, diabetes, smoking and other traditional risk factors. Risk was about 2.5-fold higher in people with more severe liver disease, especially higher fibrosis stages.
- Why: the fatty, insulin-resistant liver overproduces triglyceride-rich and LDL particles, raises blood glucose, and releases inflammatory and clotting factors โ the ingredients of atherosclerosis.
- What it means: cardiovascular disease, not liver failure, is the most common cause of death in MASLD. Cardiovascular risk assessment and treatment โ blood pressure, lipids, glucose, smoking โ is part of every MASLD plan.
- Beyond atherosclerosis: MASLD is also linked with heart failure, atrial fibrillation and thickening of the heart muscle.
Chronic kidney disease
Across 13 studies of over 1.2 million people, MASLD was associated with about a 43% higher risk of developing chronic kidney disease (reduced kidney function or protein in the urine), independent of diabetes, hypertension and obesity. The risk appears higher with more advanced liver disease. Kidney and liver disease share the same metabolic drivers โ and several of the medicines we use for MASLD (SGLT2 inhibitors, GLP-1 receptor agonists) have proven kidney benefits.
The two-way diabetes link
MASLD and type 2 diabetes are best understood as two faces of the same insulin-resistant state:
- Liver โ diabetes. A pooled analysis of over 500,000 adults found MASLD more than doubled the risk of developing type 2 diabetes, and the risk rose with the severity of liver disease. The fatty liver's unchecked glucose output is a major reason fasting sugar rises.
- Diabetes โ liver. Type 2 diabetes is the strongest clinical predictor of progression to advanced fibrosis, cirrhosis and hepatocellular carcinoma. In people with diabetes, MASH and fibrosis are common and often unrecognized.
- Improving one helps the other. Resolution of MASLD is associated with a lower risk of developing diabetes, and diabetes drugs such as pioglitazone and GLP-1 receptor agonists improve liver histology.
This is the clearest reason MASLD belongs in endocrine care: the same visit, the same labs, and often the same prescription address both.
Cirrhosis and liver cancer
In the US, roughly a quarter of adults have MASLD, about 5% have MASH, and an estimated 1โ2% have MASH with advanced fibrosis or cirrhosis. MASH is now a leading cause of liver transplantation in the US โ the leading cause in women.
Liver cancer (hepatocellular carcinoma) is the most feared complication. Most cases arise in cirrhosis, but a meaningful share of MASLD-related liver cancers occur in livers that are not cirrhotic, particularly in people with diabetes. Patients with cirrhosis need liver-cancer surveillance by ultrasound every six months, coordinated by hepatology.
When to call your doctor
- Yellowing of the skin or eyes, or dark urine.
- New swelling of the abdomen or legs.
- Confusion, unusual sleepiness, or personality change.
- Vomiting blood or black, tarry stools โ call 911.
- Chest pain, shortness of breath on exertion, or new palpitations.
What we know
- MASLD is independently associated with cardiovascular events, CKD and incident diabetes.
- Cardiovascular disease is the leading cause of death in MASLD.
- Liver risk climbs steeply from F2 fibrosis.
What we don't know
- How much of the extra heart and kidney risk is caused by the liver itself.
- Whether reversing MASH, on its own, lowers cardiovascular events.
- The best liver-cancer screening strategy for non-cirrhotic patients.
Questions to ask your doctor
- What is my 10-year cardiovascular risk, and should I be on a statin?
- Have my kidney function and urine albumin been checked?
- Given my fatty liver, how is my diabetes risk โ or my diabetes control?
- What is my fibrosis stage, and do I need liver-cancer surveillance?
How we grade evidence. Every intervention carries a plain label โ from established, guideline-supported care (A) through moderate (B) and mixed or limited (C) to experimental (D) and insufficient (E). An improvement on a liver biopsy or scan is not the same as fewer cirrhosis cases, heart attacks, or deaths, and we say which we mean.
Real questions we hear about the risks of fatty liver.
Why is my endocrinologist worried about my heart when I came in for my liver? Grade A
What the evidence shows
Pooled data from about 5.8 million people show roughly 45% higher risk of cardiovascular events with MASLD, rising to about 2.5-fold with more severe disease.
In our practice
Every MASLD plan includes blood pressure, lipid and glucose targets, and a statin when indicated. Established coronary disease is co-managed with cardiology.
Does fatty liver affect the kidneys? Grade B
What the evidence shows
Meta-analysis of 13 cohort studies (over 1.2 million people) showed a 1.43-fold risk of incident CKD.
In our practice
We check kidney function and urine albumin and favor medications โ SGLT2 inhibitors, GLP-1 receptor agonists โ that protect the kidneys too.
If my liver fat goes away, will my diabetes improve? Grade B
What the evidence shows
Observational studies show MASLD regression lowers incident diabetes risk; drugs that reduce liver fat (pioglitazone, GLP-1-based therapies) also lower A1c.
In our practice
We treat the two together and track both A1c and liver measures.
References
- Targher G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903โ913.
- Mantovani A, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71(1):156โ162.
- Mantovani A, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70(5):962โ969.
- Dulai PS, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557โ1565.
- Taylor RS, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611โ1625.
- Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691โ1705.
- Lomonaco R, et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting. Diabetes Care. 2021;44(2):399โ406.
- Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377(21):2063โ2072.
- Kanwal F, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155(6):1828โ1837.
- Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797โ1835.
Worried about your heart, kidneys, or blood sugar โ and your liver?
One plan for all of it. Board-certified endocrinologists who treat the metabolism behind MASLD.